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Extracellular Space Measurements
With CMR Imaging*
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oMyocardial viability imaging based on cardiovascu-
lar magnetic resonance (CMR) has been shown to
be helpful in the setting of both acute (1) and
chronic (2,3) ischemia, myocarditis (4,5), cardiac
sarcoidosis (6), and hypertrophic cardiomyopathy
(7,8). The mechanism underlying the utility of
CMR viability imaging most likely relates to the
close interaction between the contrast agent mol-
ecule and myocardial tissue itself. Healthy myo-
cardial tissue is characterized by tightly-packed
myocytes organized much like parallel rows of
See page 897
cylinders. The cell membrane of healthy myocytes
precludes the CMR contrast agent molecule from
entering the intracellular space, and because the
intracellular space occupies approximately 80% of
the imaging voxel, the extracellular volume fraction
(ECF) is normally approximately 20%. Irreversible
myocyte injury exposes the intracellular space to the
CMR contrast agent molecule, leading to an in-
crease in the apparent ECF, which manifests itself
in T1-weighted CMR images as a region of hyper-
enhancement that appears most conspicuously sev-
eral minutes after contrast agent administration
(“delayed hyperenhancement”). Accordingly, re-
gions of delayed hyperenhancement are indicative
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viability.f irreversible injury and, in general, portend a
orse patient prognosis (9,10).
A fundamental limitation of CMR viability im-
ging is that the technique relies on regional as
pposed to global variations in ECF. Global
hanges in ECF, for example, in a circumstance
here the ECF of the entire ventricle is homoge-
eously elevated, could be difficult to detect.
In this issue of iJACC, Mongeon et al. (11)
escribe the clinical application of a new technique
o quantify ECF on a global rather than regional
asis. Such a technique could have important ap-
lications in a clinical setting, particularly in pa-
ients with diseases characterized by global rather
han regional abnormalities in myocardial tissue
tructure, such as infiltrative diseases.
verview of the new technique. The technique de-
cribed by Mongeon et al. (11) essentially involves
dministrating the same contrast agents routinely
sed for CMR and imaging several minutes later
ith a specialized but widely available CMR pulse
equence. The resulting images are then post-
rocessed with specialized software designed to
stimate the ECF on the basis of mathematical
odeling of myocardial physiology. The pulse se-
uence required for the technique is well-known
nd widely used for research purposes, and the
athematical models have already been rigorously
valuated in previous studies (12).
nderlying assumptions. The technique of Mon-
eon et al. (11) implicitly assumes that the concen-
ration of the contrast agent in the blood pool is at
quilibrium with that of the myocardial tissue at the
ime of image acquisition. There are several mech-
nisms by which this assumption could be violated.
irst, the passage of the contrast agent molecule out
f the myocardial capillaries and into the interstitial
pace is thought to have a time scale of minutes,
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909meaning that imaging must not be performed too
early after the initial contrast agent administration.
Perhaps more importantly, the time to reach equi-
librium will increase with increased values of ECF
and/or decreasing regional myocardial blood flow,
meaning that patients with significant heart disease
are the same patients most likely not to achieve
equilibrium quickly. Second, excretion of CMR
contrast agents occurs largely by glomerular filtra-
tion with a time scale of 10s of minutes (13). Such
a time scale is similar to that needed to image the
patient over a 30-min period to determine ECF.
Third, blood clearance of the contrast agent is
altered in patients with amyloid (14). Despite these
physiological assumptions, however, all would ap-
pear reasonable to first order.
The technique also relies on several assumptions
related to CMR. Perhaps the most important of
these relates to the Look-Locker CMR pulse se-
quence, which samples the T1 relaxation curve
multiple times after the inversion pulse. Image
acquisition is performed serially throughout the
cardiac cycle without regard for cardiac motion, and
T1 values can only be derived for regions of interest
(ROIs) that must be manually adjusted for each
image and therefore are subject to misregistration
effects (15). Like the physiological assumptions,
however, the CMR assumptions would also appear
reasonable to first order.
Clinical practicality. In its current form the technique
requires manual tracing of both the endocardial and
epicardial border of the left ventricle in the 17
different images acquired after the adiabatic inver-
sion pulse. Each of the 17 images must then be
divided into 6 radial segments, and each of the 6
segments must be fit to a monoexponential relax-
ation curve to determine myocardial T1. All of the
A
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Figure 1. Possible Structural Changes to the Myocardium as a F
ECF  extracellular volume fraction.preceding steps must be repeated 4 times: once forthe single set of pre-contrast images, and 3 times for
the 3 sets of post-contrast images. The resulting 4
T1 values (per segment) must then be fit to a
straight line to determine ECF. In the paper by
Mongeon et al. (11), the ECF estimates were
performed on a single short-axis slice; full heart
coverage would require that all of the aforemen-
tioned processes to be repeated 6 to 8 times.
Justifying the time needed to perform these post-
processing steps routinely in a clinical setting would
be difficult, although some optimization of the
current processes could probably be achieved.
Continuum of inﬁltrative disease severity. Perhaps a
ore fundamental consideration relates to the na-
ure of myocardial infiltrative disease itself. Al-
hough it seems clear that more severe disease
orresponds to an increasing amount of myocyte
oss and/or accumulation of interstitial proteins, the
xtent to which severe disease can be globally
omogeneous is less obvious. To illustrate this
oint, Figure 1 depicts possible structural changes
to the myocardium as a function of disease severity.
Mild disease (Fig. 1B) might be characterized by
increases in ECF similar to those observed by
Mongeon et al. (11) in patients with non-amyloid
cardiomyopathy, in which ECF averaged 0.33 and
whose error bars overlap with ECF values in vol-
unteers (see Fig. 2 of Mongeon et al. [11]). Mild
disease might have prognostic implications, but
because the error bars overlap, it might be difficult
to determine whether an individual patient does or
does not have mild infiltrative disease. Conversely,
although severe disease might be easier to detect, it
is also possible that severe infiltrative disease is most
commonly associated with both global and regional
elevations in ECF (Fig. 1C), the latter of which can
already be detected with routine delayed enhance-
reasing Fibrosis
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uncment techniques. Arguably, evidence supporting
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910this perspective can be found in Figure 3A of
Mongeon et al. (11). Specifically, the data points
that lie on the vertical axis of Figure 3A might
represent both patients with no disease and also
patients with mild disease (Figs. 1A and 1B),
hereas the data points on the right side of the
ertical axis represent patients with severe disease
Fig. 1C) that have both global elevations in ECF
nd also have regional hyperenhancement that can
e identified by delayed enhancement techniques.Myocardial scar visualized by cardio-
vascular magnetic resonance imaging
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Kushner JD, et al.
resonance imaginhypothesis that the technique of Mongeon et al.
(11) can systematically identify patients with a
purely global form of infiltrative disease and/or that
this technique provides prognostic information that
is not already being provided by routine delayed
enhancement imaging.
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